↓ Skip to main content

Dove Medical Press

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia

Overview of attention for article published in OncoTargets and therapy, August 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
51 Mendeley
Title
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
Published in
OncoTargets and therapy, August 2013
DOI 10.2147/ott.s36980
Pubmed ID
Authors

Kimberly E Price, Najma Saleem, Georgina Lee, Michael Steinberg

Abstract

Development of BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. However, resistance or intolerance to these TKIs still leaves some patients without many treatment options. One point mutation in particular, the T315I mutation, has been shown to be resistant to first and second generation TKIs. The third generation TKI, ponatinib, may provide an option for these patients. Ponatinib (Iclusig®), an orally available, pan-tyrosine kinase inhibitor has a unique binding mechanism allowing inhibition of BCR-ABL kinases, including those with the T315I point mutation. A Phase II study evaluated ponatinib in patients who were resistant or intolerant to nilotinib or dasatinib or patients who had the T315I mutation. In the Phase II study, ponatinib produced a major cytogenetic response in 54% of chronic phase chronic myeloid leukemia patients. It further achieved major hematologic response in 52% of patients in the accelerated phase, 31% of patients in the blast phase, and 41% of Philadelphia chromosome positive acute lymphoblastic leukemia patients. Ponatinib also showed efficacy in patients with the T315I mutation. Serious adverse events included arterial thrombosis, hepatotoxicity, cardiovascular risks, pancreatitis, hemorrhage, fluid retention, myelosuppression, rash, abdominal pain, and embryo-fetal toxicity. Due to the risk of these adverse events and potential drug interactions, the use of ponatinib must be carefully weighed against the benefits in treating patients who have limited treatment options.

Timeline
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 14%
Researcher 6 12%
Student > Master 6 12%
Student > Bachelor 6 12%
Student > Doctoral Student 3 6%
Other 10 20%
Unknown 13 25%
Readers by discipline Count As %
Medicine and Dentistry 14 27%
Agricultural and Biological Sciences 7 14%
Biochemistry, Genetics and Molecular Biology 6 12%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Computer Science 2 4%
Other 4 8%
Unknown 14 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2014.
All research outputs
#8,446,341
of 26,673,263 outputs
Outputs from OncoTargets and therapy
#464
of 3,038 outputs
Outputs of similar age
#66,043
of 212,067 outputs
Outputs of similar age from OncoTargets and therapy
#11
of 41 outputs
Altmetric has tracked 26,673,263 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,038 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,067 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.